Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates.

Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 billion, according to Benzinga Pro. The company reported quarterly earnings of $2.11 per share, which beat analyst estimates of $2.06 per share.

Salesforce shares gained 9.4% to $252.00 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

• Aditxt, Inc. ADTX shares rose 126.1% to $7.80 in pre-market trading.
• Connexa Sports Technologies Inc. CNXA shares rose 74.7% to $0.5987 in pre-market trading. Connexa Sports recently reported a decline in sales for the second quarter.
• Clearmind Medicine Inc. CMND rose 50.1% to $6.08 in pre-market trading after surging 22% on Wednesday. Clearmind Medicine recently announced results from its weight loss and metabolic disorder program.
• Ampio Pharmaceuticals, Inc. AMPE shares surged 37.7% to $2.70 in pre-market trading after gaining over 3% on Wednesday.
• Avenue Therapeutics, Inc. ATXI shares rose 33.4% to $0.2326 in pre-market trading after falling 8% on Wednesday. Robert Davidow reported a14.5 % passive stake in Avenue Therapeutics in a 13G Filing Tuesday.
• Minim, Inc. MINM gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday.
• VinFast Auto Ltd. VFS gained 24.3% to $9.40 in pre-market trading after gaining around 8% on Wednesday.
• Cyclacel Pharmaceuticals, Inc. CYCC shares climbed 18.5% to $0.3519 in pre-market trading. Cyclacel recently received notification of deficiency from Nasdaq regarding timely filing of quarterly report on form 10-Q.
• Neumora Therapeutics Inc NMRA gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of NMRA-266 in healthy adult participants for schizophrenia and other neuropsychiatric disorders.

Losers

• Vivos Therapeutics, Inc. VVOS dipped 32.9% to $27.51 in pre-market trading. Vivos Therapeutics shares jumped around 832% on Wednesday after the company announced it received FDA 510(k) clearance for treating severe obstructive sleep apnea in adults using the Vivos' removable CARE oral appliances.
• RedHill Biopharma Ltd. RDHL shares fell 21.5% to $2.26 in pre-market trading after gaining 26% on Wednesday. On Monday, Redhill Biopharma announced that the FDA had granted five years' market exclusivity for its drug, Talicia, on top of three years' exclusivity granted for the approval of Talicia.
• Nvni Group Limited NVNI shares fell 19.2% to $1.89 in pre-market trading after gaining over 5% on Wednesday.
• Apollomics, Inc. APLM fell 18.5% to $0.92 in pre-market.
• Yoshiharu Global Co. YOSH shares fell 16.2% to $7.72 in pre-market trading. Yoshiharu Global shares jumped 93% on Wednesday after the company effected a 1-for-10 reverse stock split for its Class A and Class B common stock.
• Pure Storage, Inc. PSTG fell 15.7% to $31.95 in pre-market trading after the company reported worse-than-expected third-quarter revenue results and issued FY24 revenue guidance below estimates.
• ProSomnus, Inc. OSA shares fell 15.6% to $0.7933 in pre-market trading after gaining 23% on Wednesday.
• Pasithea Therapeutics Corp. KTTA shares fell 15.3% to $0.2997 in pre-market trading after gaining around 7% on Wednesday
• C3is Inc. CISS fell 14% to $0.4555 in pre-market trading after jumping 21% on Wednesday.
• Safe and Green Development Corporation SGD fell 10.4% to $2.37 in pre-market trading after dipping 14% on Wednesday.

Now Read This: Investor Optimism Edges Lower Following GDP Data